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In solid organ transplantation, mesenchymal stem cell (MSC) therapy is strongly emerging among other cell
therapies due to the positive results obtained in vitro and in vivo as an immunomodulatory agent and their
potential regenerative role. We aimed at testing whether a single dose of MSCs, injected at 11 weeks after kidney
transplantation for the prevention of chronic mechanisms, enhanced regeneration and provided protection
against the inflammatory and fibrotic processes that finally lead to the characteristic features of chronic allograft
nephropathy (CAN). Either bone marrow mononuclear cells (BMCs) injection or no-therapy (NT) were used as
control treatments. A rat kidney transplantation model of CAN with 2.5 h of cold ischemia was used, and
functional, histological, and molecular parameters were assessed at 12 and 24 weeks after transplantation. MSC
and BMC cell therapy preserves renal function at 24 weeks and abrogates proteinuria, which is typical of this
model (NT24w: 68.9 – 26.5 mg/24 h, MSC24w: 16.6 – 2.3 mg/24 h, BMC24w: 24.1 – 5.3 mg/24 h, P < 0.03). Only
MSC-treated animals showed a reduction in interstitial fibrosis and tubular atrophy (NT24w: 2.3 – 0.29,
MSC24w: 0.4 – 0.2, P < 0.03), less T cells (NT: 39.6 – 9.5, MSC: 8.1 – 0.9, P < 0.03) and macrophages (NT: 20.9 – 4.7,
MSC: 5.9 – 1.7, P < 0.05) infiltrating the parenchyma and lowered expression of inflammatory cytokines while
increasing the expression of anti-inflammatory factors. MSCs appear to serve as a protection from injury de-
velopment rather than regenerate the damaged tissue, as no differences were observed in Ki67 expression, and
kidney injury molecule-1, Clusterin, NGAL, and hepatocyte growth factor expression were only up-regulated in
nontreated animals. Considering the results, a single delayed MSC injection is effective for the long-term pro-
tection of kidney allografts.
Introduction
Chronic allograft nephropathy (CAN) is a multifac-torial process that leads to late allograft dysfunction in
renal transplantation. The joint association of nonalloreactive
factors, as cold ischemia, and allogeneic factors significantly
increases cellular infiltration at both early and late stages,
aggravating the progression of CAN, which has been clearly
shown in experimental models [1]. The main features of this
entity include at end stages severe interstitial fibrosis and
tubular atrophy (IFTA) with loss-of-renal function.
Cell therapies applied to solid organ transplantation have
gained interest in the last years, and among them, mesen-
chymal stem cell (MSC) therapy has been strongly emerging.
In addition to their potential role in therapies for renal repair,
the immunomodulatory properties of MSCs offer promise as
a novel cellular therapy for kidney transplantation.
To date, 3 groups have approached MSC cell therapy in
the experimental kidney transplantation field but focusing
only on the acute kidney injury [2–5]. The use of donor MSCs
has been shown to induce tolerance and regulatory T-cell
expansion by the induction of indoleamine 2,3-Dioxygenase
(IDO) expression [2], while allogeneic MSCs enhanced
functional recovery and attenuated histological damage from
acute rejection by reducing cellular infiltrate in a 7 day follow-
up in both syngeneic and allogeneic models of kidney trans-
plantation [3,4]. Contrarily, Zhang et al. [5] did not observe
a beneficial effect of treatment with MSCs (undetermined
source) compared with cyclosporine A (CsA) monotherapy
in a rat allogeneic kidney transplantation model.
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MSCs treatment has also been tested in native chronic
kidney disease models. In a 5/6 nephrectomy model, allo-
geneic MSCs injection decreased proteinuria and fibrosis
[6–8] when intravenously injected or under the renal cap-
sule, while the comparison between bone marrow mono-
nuclear cells (BMCs) and MSCs injected in the renal
parenchyma showed a better outcome with BMC cell
therapy [9]. In a Col4A3 knock-out chronic model, synge-
neic MSCs were able to reduce interstitial fibrosis [10],
while allogeneic MSCs did not ameliorate the progression
of the disease [11].
Moreover, acute kidney rejection can be effectively pre-
vented in the early stages by using conventional drug-based
immunosuppression, but unfortunately, there are no efficient
immunosuppressive regimens that are able to guarantee
long-term graft acceptance. Nowadays, the progressive loss
of function secondary to IFTA is the major cause of graft loss.
In this work, we tested the effect of delayed therapy with
an intravenous injection of a single dose of allogeneic BMCs
or bone marrow-derived MSC on established CAN. We,
specifically, assessed the potential immune mechanisms, the
outcome of regeneration, and the protection against the in-
flammatory and fibrotic processes that finally lead to the




For renal transplantation, inbred male Lewis rats (MHC
haplotype: RT1I) (250 g body weight; Charles River) received
a kidney from male Fischer-344 rats (MHC haplotype:
RT1Iv1) (250 g body weight, Charles River) as previously
described [12–14]. Briefly, kidneys were 2.5 h preserved in
EuroCollins at 4C. Recipient rats were bi-nephrectomized at
the moment of transplantation. The animals received a single
daily dose of 5 mg/kg CsA (Novartis) by oral gavage for 15
days. This model develops proteinuria and progressive renal
damage [13]. All the procedures and housing conditions
were in accordance with the guidelines of the Committee on
the Care and Use of Laboratory Animals and Good La-
boratory Practice.
Study design and follow-up
Rats were divided into 3 groups of treatment: NT: No-
therapy group (n = 11); BMC: BMCs injection (n = 12); and
MSC: MSCs injection (n = 14). One rat was transplanted
every day, and rats were included in 2 different badges of
correlative transplantations (first badge: 21 animals, second
badge: 15 animals). Before transplantation and then
monthly until the end of the study, the rats were weighed
and placed in metabolic cages for 24 h-urine and tail vein
blood collection. Urine and serum creatinine (mM) were
determined by Jaffe’s reaction (Beckman Instruments), and
proteinuria (Prot, mg/24 h) was determined by Ponceau’s
method (Bayer Diagnostics). Serum creatinine levels were
assessed on days 1, 3, 5, and 7 after cell therapy. One week
after cell therapy (12 weeks after transplantation), some rats
were sacrificed (n = 4 for NT and BMC and n = 7 for MSC),
and the grafted kidney was processed for histological and
molecular studies. At the end of the study (24 weeks), the
rest of the animals were sacrificed, and the grafted kidney
was also processed.
Cell preparation and injection
Male Sprague-Dawley green fluorescent protein (GFP)
transgenic rats (GenOway) weighing between 250 and 300 g
were used as a MSC and BMC source [15]. Briefly, the femurs
and tibias were surgically removed and flushed under sterile
conditions with phosphate buffer saline (PBS). Cells were
passed through a 70mm mesh and washed twice with PBS to
obtain BMCs. For the MSCs isolation, 60 · 106 were cultured
in 15 cm-diameter plates with DMEM (Gibco, Life Technol-
ogies) with 10% fetal bovine serum (FBS; Lonza). Between
passages 3 and 5, the cells were harvested; depleted for
CD45 + CD11b/c
+ (autoMACS; Miltenyi Biotec); stained for
CD90-Allophycocyanin (Miltenyi Biotec), CD73, MHC-I (ox-
18-PE), and MHC-II (ox-6-PE) (Becton Dickinson); and ana-
lyzed by flow cytometry (FACSCanto II and Diva software for
the analysis; Becton Dickinson). MSCs were proved to be
multipotent with a conditioning medium: IMDM (PAA) with
20% FBS, 2 mM L-glut, 0.05 mM b-Mercaptoethanol, 10 - 9
Dexamethasone supplemented with 5mg/mL Insuline for
the adipogenic medium, and 50mg/mL ascorbic acid 2-P and
10 mM b-Glycerophosphate for the osteogenic medium. A
single-cell (MSC or BMC) suspension was prepared in PBS and
maintained at 4C until the moment of the injection. All ani-
mals received, through the tail vein, 0.5 mL of PBS alone
(NT), 0.5 · 106 GFP+ cultured MSC (MSC), or 107 GFP + freshly
isolated BMC (BMC) at the 11th week after kidney transplan-
tation. The timing chosen corresponds to the increasing pro-
teinuria in this model, as previously described [12].
Histological studies
Transversal kidney graft, liver, and spleen slices (1–2 mm)
were either fixed in buffered formalin and frozen in optimal
cutting temperature compound or dehydrated and embed-
ded in paraffin. For light microscopy, tissue sections (3–4mm)
were stained with hematoxylin-eosin, periodic acid-Schiff,
and Masson’s trichrom. A pathologist blinded to the treat-
ment groups examined all sections. Glomerulosclerosis
was expressed as a percentage of damaged glomeruli, while
tubular atrophy, interstitial fibrosis, interstitial cell infiltra-
tion, and vasculopathy were graded following a semi-
quantitative scale from 0 to 3 (0, no abnormalities; + 1,
abnormalities affecting < 1/3 of the sample; + 2, between
1/3 and 2/3; + 3, > 2/3 of the sample). IF/TA was assessed
following the Banff criteria [16].
Immunohistochemistry
Representative tissue sections were immunoperoxidase
stained for connective tissue growth factor (CTGF, rabbit
polyclonal IgG; Santa Cruz Biotechnology, Inc.), alpha-
smooth muscle actin (aSMA, MS-113, Neomarkers; LabVi-
sion Ltd.), CD3 (monoclonal mouse anti-rat, Serotec; Bionova
cientifica), ED1 (Oxford Biomarketing), Ki67 (mouse anti-
rat; BD Pharmingen), and rabbit anti-rat IDO [17] and im-
munofluorescence stained for GFP (ab5450; Abcam) in par-
affin-embedded sections. The CTGF, aSMA, CD3, ED1, and
Ki67 stained samples were revealed with diaminobenzidine
(Sigma-Aldrich) and counterstained with hematoxylin. IDO
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immunostaining was performed as previously described
[17]. GFP was directly observed under fluorescence light
microscopy in kidney, liver, and spleen sections. Positive
CTGF, aSMA, and IDO samples were semi-quantitatively
scored from 0 to 3 in the tubules, the interstitial compart-
ment, or the glomeruli. Positive CD3, ED1 infiltrating, and
Ki67 tubular cells were quantitatively assessed at least in 20
power fields in a 400 magnification.
Quantification of circulating donor-specific antibodies
The presence of circulating donor-specific antibodies
(DSAs) class-I and class-II was quantified on recipient serum
samples that were incubated with donor spleen cells and
measured by flow cytometry. Plasma samples were collected
at the moment of sacrifice. Donor splenocytes were isolated
from Fischer-344 or Sprague-Dawley rat spleens by Ficoll
density gradient and freshly used. Different controls were
added: serum from nontransplanted Lewis rat as naı̈ve; se-
rum from a transplanted Lewis rat with high anti-MHC
antibody titer as a positive control.
Briefly, 5 · 105 splenocytes were incubated with 25 mL of
recipient serum for 30 min at room temperature, washed in
PBS, incubated in the dark (30 min, 4C) with a 1:25 mix of
anti-CD3 (eBioscience) and anti-IgG Fc portion ( Jackson
Immuno Research), fixed with 1% paraformaldehyde, and
analyzed by flow cytometry. A fluorescence increase of 15%
with regard to the negative control was considered positive.
Results were expressed as a percentage of positive cells with
regard to the total number of CD3 + spleen cells.
Gene expression assays
Frozen kidney tissue was homogenized in trizol reagent.
Total RNA was extracted and purified using PureLink RNA
mini kit (Invitrogen, Life Technologies). Overall, 500mg of total
RNA was retrotranscribed with a high-capacity complemen-
tary DNA reverse transcription kit (Applied Biosystems).
Negative controls for reverse transcriptions were carried out
using distilled water. Gene expression of IL4 (Rn01456866_
m1), IL6 (Rn00561420_m1), IL7 Receptor (Rn01402421_m1),
IL10 (Rn00563409_m1), IL12p40 (Rn00575112_m1), IL15
(Rn00565548_m1), IL23a (Rn00590334_g1), tumor necrosis fac-
tor alpha (TNFa, Rn99999017_m1), Fibronectin1 (Rn00569575_
m1), Ki67 (Rn01451448_g1), basic fibroblast growth factor
(bFGF, Rn00570809_m1), hepatocyte growth factor (HGF,
Rn00566673_m1), IDO (Rn00576778_m1), CXCR4 (Rn01483207_
m1), CXCL12 (Rn00573260_m1), Clusterin (Rn00562081_m1),
NGAL (Rn00590612_m1), and kidney injury molecule-1 (KIM-1,
Rn00597703_m1) was performed by Taqman assay in a 7900HT
real-time polymerase chain reaction (PCR) system (Applied
Biosystems) by relative to 18S quantification using the CT
method. PCR reactions and amplification were performed as
previously described [12]. The gene expression of NT12w kid-
neys was used as reference values. Results were expressed as
many folds of the unknown sample with regard to the reference
value (arbitrary units).
Statistical analysis
Serum creatinine differences at any time point, DSA, gene
expression, and plasma proteins were analyzed by analysis
of variance and subsequent Scheffe’s test. For a histological
comparison of Banff classification, a Chi Square P value was
calculated from the contingency table. A semi-quantitative
histological evaluation was analyzed through the non-
parametric Kruskal–Wallis test. Two-tailed P < 0.05 was
considered statistically significant. Data are presented as
mean – SEM.
Results
MSCs show low immunogenicity
MSCs were isolated by plastic adherence, and the CD45- ,
CD11b/c
- , and CD90 + , CD73 + subpopulation was used for
cell therapy. The multipotentiality of these cells was proved
by their ability to differentiate into adipocytes or osteocytes
(data not shown). They were selected for the therapy given
their low immunogenicity, as they did not express MHC-II
and had a very low expression of MHC-I (Fig. 1A, B). Con-
trarily, BMCs expressed MHC-II and, especially, MHC-I.
Moreover, rats treated with MSCs did not develop cell
DSAs against Sprague-Dawley MHC class I or class II early
post-transplantation, while rats receiving BMCs developed
high levels of DSA against Sprague-Dawley MHC-I within
the first week after a cell injection (Fig. 1C). As expected, NT
rats did not present circulating antibodies against Sprague-
Dawley (data not shown), indicating specificity of the cir-
culating antibodies present in both cell treatment groups of
animals.
MSCs prevent from renal dysfunction
All the animals followed up to 24 weeks post-transplan-
tation survived the study period. As shown in Fig. 2, the
animals that were not treated developed progressive pro-
teinuria and renal insufficiency from the 12th week onward.
In marked contrast, the animals receiving either BMCs or
MSCs therapy had no increase in proteinuria and also pre-
served normal serum creatinine levels.
One week after treatment, there was no difference in
kidney function between PBS and MSC or BMC treatment.
MSCs preserve renal histology along the follow-up
As expected, at 24 weeks, the conventional histology of
NT grafts showed extensive tubular atrophy with wide-
spread interstitial fibrosis and moderate diffuse interstitial
infiltration (Fig. 3). Although those kidney grafts displayed a
diverse degree of damage, most of them showed the highest
IFTA values among the 3 groups of treatment (Mean value:
2.3, Fig. 3A). The MSC grafts displayed a normal histological
picture with minimal tubular atrophy, interstitial fibrosis,
and cellular infiltration (Fig. 3F). This resulted in very low
IFTA scores in this group, contrary to NT (Mean value: 0.4).
BMCs-injected animals presented the most heterogeneous
histological damage distribution with IFTA scores ranging
from 0 to 3 (Mean value: 1.6), significantly higher than
the ones of the MSC group but not lower than the ones of the
NT group.
Even though the 3 groups showed similar initial IFTA at
12 weeks (data not shown), MSC treatment appeared to
decrease the number of infiltrating cells within the first week
after therapy compared with the other 2 groups, and inter-
estingly, BMCs-injected animals slightly increased interstitial
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infiltrate mainly composed of ED1 + macrophages. It is worth
mentioning that the MSC injection prevented the inflam-
matory infiltrate also at 24 weeks and maintained lower
IFTA values until the end of the study, suggesting a pre-
ventive rather than corrective role of this cell therapy.
Although the model is not characterized by severe
vasculopathy, both cellular treatments reduced vascu-
lar damage at 24 weeks. Notably, cellular therapy also
halted the progression of glomerulosclerosis development
(Fig. 3F).
FIG. 1. MSCs are low-immunogenic cells. Levels of MHC-I (A) and MHC-II (B). MSCs (dashed line) express low levels of
MHC-I and are negative for MHC-II, while BMCs (gray line) express high levels of MHC-I and low levels of MHC-II. As a
positive control of MHC-I and MHC-II expression, we used Sprague-Dawley rat splenocytes (black line). We also quantified
the percentage of DSA against third-party injected cells (MSCs or BMCs) 1 week after the injection (C), and observed no
antibodies in MSC-injected animals (open bars) and positive MHC-I in BMC-injected animals (gray bars) (bP = 0.005, cP = 0.06).
MSC, mesenchymal stem cell; BMCs, bone marrow mononuclear cells; DSA, donor specific antibody.
FIG. 2. MSCs and BMCs prevent from developing late allograft dysfunction. The animals treated with MSCs or BMCs did
not increase the proteinuria levels, reaching significant differences at 20 and 24 weeks when compared with NT animals
(P < 0.05). In parallel, serum creatinine levels were nonpathologically maintained in both cell-injected groups (*P < 0.05 NT vs.
BMC, **P < 0.001 vs. MSC, ***P < 0.001 NT vs. MSC and BMC). NT, no-therapy.
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MSCs modulate the immune-inflammatory response
Further immunohistochemical analysis revealed that a
BMC injection immediately recruited increased numbers
of ED1 + (macrophages) infiltrating cells with regard to
NT- and MSC-treated animals at 12 weeks (Fig. 3F). At
this time point, MSC therapy reduced the number of
both ED1 + and CD3 + infiltrating cells not only with re-
gard to the BMC group but also with regard to the NT
group (Fig. 3F), and this observation persisted at 24
weeks. Contrarily, ED1 + and CD3 + infiltrating cells in
NT animals increased at 24 weeks. BMC-injected animals
maintained the number of infiltrating macrophages over
time and highly increased the number of infiltrating T
lymphocytes.
In accordance, MSC-treated animals showed a reduc-
tion in the parenchymal gene expression of inflammation-
related genes along the follow-up, especially in IL6,
IL23a, and IL7R (Table 1), although no differences
were observed in IL15, IL12p40, or IL4 (data not shown).
Furthermore, we also observed an immediate anti-
inflammatory effect of MSC treatment through low gene
expression of TNFa 1 week after cell therapy (NT12w:
1.00 – 0.00, BMC12w: 0.97 – 0.23, MSC12w: 0.49 – 0.10a,b;
P < 0.05 a: vs. NT, b: vs. BMC) along with a long-term
effect on the up-regulation of the anti-inflammatory IL10
at 24 weeks (Table 1).
The immunomodulatory properties of MSC are sup-
ported by the IDO expression. An immunohistochemical
analysis showed an increase of this protein in the MSC
grafts at 24 weeks (Fig. 3F). The gene expression showed a
logarithmic up-regulation a long time after the cell treat-
ment (Fig. 4). In BMC-treated animals, IDO was 10-fold
over-expressed with regard to NT at 24 weeks, but this
was still far under the expression level reached by MSC
treatment.
FIG. 3. Conventional histology. NT animals showed the worst outcome when pathological histology was analyzed (A). Not
only IFTA degree in MSC animals was lower compared with NT animals, but also BMC animals show the worst histological
preservation (P < 0.003 vs. NT, P < 0.05 vs. BMC). (B) and (C) are representative pictures of the NT kidney at 24 weeks of PAS
and Masson staining, respectively. (D) and (E) show better-preserved and also less fibrotic MSC kidneys at 24 weeks with the
same staining. In (F), we have specified the histological parameters evaluated by a pathologist at 12 and at 24 weeks and
immunohistochemical-staining quantification of lymphocytic (CD3) and macrophagic (ED1) infiltrates (mean positive cells/
field viewed – SEM) as well as semi-quantitative evaluation of IDO expression (score 0 to 3), (aP < 0.05 vs. NT group at the
same time point, bP < 0.05 vs. BMC group at the same time point, cP < 0.05 vs. same group at 12 weeks). IDO, indoleamine 2,3-
dioxygenase; IFTA, interstitial fibrosis and tubular atrophy.
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MSCs prevent from anti-donor-specific
humoral responses
Without treatment, at 12 weeks, transplanted animals
developed kidney DSAs against Fischer-344 MHC class I
(DSA-I) but not against MHC class II (DSA-II, below 15%).
Both DSA-I and DSA-II levels significantly increased over
time in these NT animals.
MSC or BMC cell injections had a different effect in the
development of DSA. The BMC animals presented DSA-I
levels similar to NT rats and higher levels of DSA-II.
In contrast, MSC treatment protected from DSA-I and
DSA-II development at 12 weeks, and despite increasing
over time, at 24 weeks, both DSA-I and DSA-II levels were
still considerably reduced compared with NT animals
(Table 2).
Table 1. Gene Expression
NT BM MSC
Gene name 12 weeks 24 weeks 12 weeks 24 weeks 12 weeks 24 weeks
Inflammation
Il6 1.00 – 0.00 1.19 – 0.53 1.14 – 0.40 0.61 – 0.13a 0.99 – 0.31 0.58 – 0.15a
Il7r 1.00 – 0.00 1.02 – 0.26 0.83 – 0.18 0.79 – 0.17 0.98 – 0.21 0.58 – 0.14a
Il23a 1.00 – 0.00 0.82 – 0.11 0.87 – 0.23 0.653 – 0.284 0.77 – 0.79 0.55 – 0.38a
Il10 1.00 – 0.00 0.93 – 0.38b 0.95 – 0.26 0.68 – 0.21 0.51 – 0.13 1.03 – 0.37b
Fibrosis
bFGF 1.00 – 0.00 1.14 – 0.22 0.66 – 0.22 0.51 – 0.21a 0.41 – 0.06a 0.59 – 0.14a
Fibronectin 1.00 – 0.00 0.42 – 0.15c 0.64 – 0.14 0.41 – 0.14 0.43 – 0.10a 0.59 – 0.14a
Homing
Cxcl12 1.00 – 0.00 0.51 – 0.15c 0.40 – 0.053a 0.57 – 0.05 0.44 – 0.036a 0.43 – 0.04
Cxcr4 1.00 – 0.00 0.52 – 0.13c 0.66 – 0.22a 0.37 – 0.07 0.4 – 0.09a 0.31 – 0.02
Immunomodulation of gene expression analysis of the grafts at 12 and at 24 weeks shows a modulation in the immune response. Results
are presented as folds versus NT 12 weeks. We observe a decrease over time in the inflammatory cytokine levels in MSC-treated animals,
along with an increase in the anti-inflammatory cytokine IL10. Fibrosis gene expression analysis (expressed as many folds over NT12 weeks)
revealed an early effect of MSC therapy, decreasing the expression of profibrotic genes. At 24 weeks, we only observe differences at a gene
level in the expression of basic fibroblast growth factor. On the other hand, at 12 weeks, the expression of homing genes CXCL12 and CXCR4
was down-regulated in both treated groups, and no differences were observed at 24 weeks (aP < 0.05 vs. NT group at the same time point,
bP < 0.05 vs. BMC group at the same time point, cP < 0.05 vs. same group at 12 weeks).
MSC, mesenchymal stem cell; BMC, bone marrow mononuclear cell; NT, no-therapy.
FIG. 4. IDO gene expression. The gene expression of IDO
in transplanted kidneys was analyzed by quantitative poly-
merase chain reaction. Results are normalized by the ex-
pression of housekeeping gene 18S and expressed as many
folds of the NT at 12 weeks (y axis). MSC-treated animals (-o-)
have increased the levels of IDO at 12 weeks that signifi-
cantly increase at 24 weeks with regard to BMC treatment (-
x-) and NT kidneys (-D-) (aP < 0.05 vs. NT, bP < 0.05 vs. BMC).
Table 2. Mesenchymal Stem Cells Injection Reduces
Kidney Donor-Specific Antibody Levels
% F344 DSA-I
12 weeks 24 weeks P
NT 54.3 – 19.9 86.1 – 2.284 0.043
BMC 65.8 – 13.5 46.8 – 15.5a NS
MSC 16.1 – 5.25b 35.1 – 15.9a NS
% F344 DSA-II
12 weeks 24 weeks P
NT 8.87 – 4.9 31.6 – 5.2 0.03
BMC 22.4 – 6.6 17.1 – 6.1 NS
MSC 1.6 – 1.2b 15.5 – 7.1c NS
The presence of circulating DSA class-I and class-II was quantified
on recipient serum samples incubated with kidney donor (F344)
spleen cells and measured by flow cytometry. A fluorescence
increase of 15% with regard to the negative control was considered
positive. Results were expressed as a percentage of positive cells
with regard to the total number of CD3 + spleen cells. DSA titters
were analyzed by analysis of variance followed by Scheffe’s test.
MSC treatment protects from developing DSAs from 1 week after the
injection (12 weeks) and at 24 weeks. The BMCs injection has a
different reaction, increasing the DSAs at 1 week after cell transplan-
tation and maintaining them along with time.
aP £ 0.04 versus NT, bP = 0.06 versus BMC; cP = 0.06 versus NT.
DSAs, donor specific antibodies.
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MSCs abrogate the onset of parenchymal fibrosis
At 12 weeks, no histological differences were observed in
the conventional histology (Fig. 3F) or in the immunohisto-
chemistry (IHC) of fibrosis markers (Fig. 5A) among the 3
groups. Nonetheless, the effect of MSC cell therapy was re-
flected at a gene level in the down-regulation of bFGF and
fibronectin gene expression 1 week after the cell injection
(Table 1). At 24 weeks, the expression of fibronectin was
equivalent in the 3 groups of study, but bFGF gene expres-
sion was still significantly lower in MSC and also in BMC
animals compared with NT (Table 1).
At 24 weeks, a conventional histology evaluation showed a
dramatic decrease in the glomerular and interstitial fibrosis in
MSC-treated animals compared with NT (Fig. 3F). This effect is
accompanied by a lower CTGF protein expression in both
tubuli and glomeruli, in the MSC-treated kidneys. BMC treat-
ment also reduced CTGF expression, only in the tubuli, al-
though remaining significantly higher than MSC kidneys (Fig.
5). A similar pattern of reduced aSMA protein expression was
observed in both glomeruli and interstitium, as shown in Fig. 5.
Cell homing is not enhanced by cell therapy
The expression of the cell homing genes (Cxcl12, Cxcr4) in
the renal parenchyma was down-regulated at 12 weeks in
both MSC and BMC groups, although at 24 weeks, these
differences had already disappeared (Table 1).
On the other hand, the presence of injected MSC or BMC
cells within renal, hepatic, and spleen parenchyma was
FIG. 5. Parenchymal fibrosis. (A) shows the semi-quantitative analysis of CTGF and aSMA tissular expression (score 0 to 3).
We observe lower aSMA parenchymal expression in MSC compared with NT at 24 weeks, and also lower CTGF tubular and
glomerular expression when compared with both NT and BMC groups (aP < 0.05 vs. NT group at the same time point,
bP < 0.05 vs. BMC group at the same time point). (B) depicts representative histological slides from all groups stained for
aSMA and CTGF (400 magnification). CTGF, connective tissue growth factor. aSMA, alpha-smooth muscle actin.
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assessed not only by direct GFP + observation on frozen tis-
sue but also by the enhancement of GFP by specific im-
munostaining in either frozen or paraffin-embedded tissues.
We could not find GFP + cells in any parenchyma either early
after cell infusion at 12 weeks or lately at 24 weeks, in any of
the treatment groups (data not shown).
MSC therapy prevents injury
We stained tissue slides for Ki67 to check whether these
protected tissues would show a higher number of positive
proliferating tubular or glomerular cells. No differences were
observed between the 3 groups of treatment neither at 12 nor
at 24 weeks. A further analysis of the gene expression of Ki67
also showed no differences at 24 or at 12 weeks between any
of the groups (Fig. 6).
When we checked for the expression of other genes in-
volved in tubular damage and regeneration after injury such
as Havcr1 (Kim-1), Lcn2 (NGAL), Clu (Clusterin), and HGF,
the results were completely different. The expression of these
genes was only up-regulated in the NT group both at 12
and/or at 24 weeks; meanwhile, both cell treatments abro-
gated the over-expression in time in these 3 genes. On the
contrary, the dynamics of HGF was somewhat different,
showing an initial increase in NT animals and a decrease
over time in all groups.
Discussion
In this study, we observed for the first time the long-term
beneficial effect of the MSC injection in a well-described
CAN model. The rationale of using MSCs in this setting rose
from the proposed immunomodulatory and remodelative
properties of these cells [8,18]. In this model, these properties
would help decrease the immune infiltrate, enhance renal
parenchyma regeneration, and, therefore, counterbalance
the fibrotic and inflammatory-driven chronic injury pro-
cesses [1]. Our experience shows that an injection of MSCs or
BMCs serves as protection from the development of pro-
teinuria, glomerulosclerosis, and vasculopathy, typically
observed in CAN, and also maintains stable function; albeit
only MSC-injected animals showed decreased numbers of
infiltrating cells, a fully preserved parenchyma structure, and
were protected from developing graft fibrosis with a very
homogeneous effect. However, we could not find any sign
of kidney regeneration or homing of the injected cells in
the graft.
Our main contribution to the success in the treatment of
the CAN is the timing of the therapy, which leads to a
complete prevention or protection of the graft 24 weeks after
transplantation. A recent report from a clinical trial treating
at the early stages after transplantation [19] showed the
unexpected deleterious short-term effects of MSC therapy.
We chose a later time after transplantation, as we and others
[20] have shown a second deleterious inflammatory wave
that leads to chronic tissue fibrosis. This type of approach has
proved successful in our group with the use of HGF gene
therapy [1].
An important point that needs to be addressed is the fact
that we did not detect any of the injected MSCs 7 days after
the therapy. As other authors have reported [21] those cells
get trapped in the lungs within hours, and no cells or fluo-
rescent signal is detected 3 days after the injection, suggest-
ing that allogeneic MSCs die in the lungs early after the
injection or are cleared from the circulation by immune cells.
However, we know that the injected cells are low MHC class
I expressers and MHC Class II negative before the injection,
which theoretically makes them immune privileged to
clearance by the adaptive immune system although more
susceptible to the innate immune system. We cannot confirm
whether there is a phenotypic change after an injection, as
some authors have proved both MHC I and MHC II up-
regulation after IFNg stimulus in vitro [22]. However, the
fact that the MSC-injected animals do not generate specific
antibodies against the 3rd party cell donor, contrary to what
happens in the BMC group, confirms that MSCs are not re-
jected by the recipient. Another option that should be con-
templated is the possibility of MSCs being eliminated by
CD8 T cells, as has been reported in vitro [23].
The use of BMCs as a therapeutic tool in solid organ
transplantation had been already attempted in experimen-
tal [9] and clinical models [24] with very good results as a
pro-tolerogenic agent. More recently, it has been suggested
that whole BMCs would be more efficient in comparison to
MSCs in the reduction of the progression of chronic kidney
[9] and heart [25,26] diseases. We, therefore, injected whole
BMC as a control group to MSC therapy. Since whole BMC
includes MSCs, they represent a better control than sham
injections.
Gene expression gives us a more precise insight of the
immune regulation while observing a decreased expression
of inflammatory genes with a clear down-regulation over
time, and an increased expression of anti-inflammatory and
immunosuppressive genes. IDO appears to be a key factor in
this regulation, as it is highly up-regulated in MSC-treated
animals. IDO can block activation of T cells, which are par-
ticularly sensitive to loss of tryptophan [27]. Notably, IDO is
needed to prevent T-cell-mediated rejection [28,29], and it
has been shown to be responsible, at least in part, for the
induction of kidney allograft tolerance through the genera-
tion of regulatory T cells in a mouse model of acute allograft
rejection [2] and in a solid organ transplantation model, be-
ing also required for organ acceptance [30].
MSC cell therapy served as a protection not only from
inflammatory cellular infiltrate but also from humoral re-
sponses. This is in tune with in vitro findings [31] show-
ing how MSC suppress allo-specific antibody production by
B cells. Interestingly, BMC therapy rapidly increases circu-
lating alloantibodies specific against the cell donor along
with an increase in circulating alloantibodies against the
kidney donor.
Along with this cellular and humoral anti-inflammatory
effect of the MSC early after treatment, we observe a gene
modulation of pro-fibrotic genes. Shortly after the injection,
MSCs show the ability to down-regulate bFGF and fibro-
nectin, while without them, treatment would be increased.
The down-regulation of fibronectin at the onset of the fibrotic
process and the effective long-term down-regulation of bFGF
are unequivocal signs of fibrosis inhibition or protection
from damage by the treatment [32,33]. At 24 weeks, the anti-
fibrotic effect may be seen in conventional histology and IHC
with a significant decrease in CTGF and aSMA.
Interestingly, this effect was maintained along with time,
although the cells were found neither at 24 weeks nor 1 week
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after the injection. CXCL12 expression has been widely
shown to play a role in the mobilization and homing of
CXCR4 + cells enhanced by tissue injury or DNA damage
[34,35]. Since the expression of these 2 factors is only early
enhanced in the non-MSC-treated groups, it gives strength to
our idea of injury blockage by the cell therapy.
As a last step, we aimed at testing tissular regeneration. It
remains controversial whether the differentiation of MSCs is
produced, as some authors have localized injected MSC in
chronic injury models and reported a regenerative effect [10],
but they have not been able to observe kidney structures or
cells derived from the injected MSCs. In our model, although
FIG. 6. Renal regeneration. Ki67 immunostaining of tubular epithelial cells (bars chart) was quantitatively assessed and
expressed as mean of positive cells/per field viewed, and showed no differences between the groups at 12 or at 24 weeks.
Gene expression of Ki67 shows slightly less expression at 12 weeks in the MSC group compared with the BMC group.
Damage/proliferation markers as Kim-1, NGAL, and Clusterin show a dramatic increase in NT compared with MSC- and
BMC-injected animals. HGF show the opposite pattern but again confirming no regeneration in the cell treatment group
(aP < 0.05 vs. NT group at the same time point, bP < 0.05 vs. BMC group at the same time point, cP < 0.05 vs. same group at 12
weeks). HGF, hepatocyte growth factor; KIM-1, kidney injury molecule-1.
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we were expecting a pro-regenerative effect, we have ob-
served neither the differentiation of injected MSCs in the
renal parenchyma similar to that proposed by some authors
nor the enhancement of regeneration. Since we have not
detected the injected MSCs in the renal parenchyma or in
liver or spleen, we cannot contribute to this subject.
Moreover, we observed a decreased expression of Kim-1,
NGAL, clusterin, and HGF. The expression of these genes
has been used as a biomarker of acute kidney damage
and is also related to the regeneration to overcome injury
[36–40]. Both cell treatments show no increase in the ex-
pression of these 4 genes in time along with a conserved
parenchyma, indicating a prevention of the damage settling
and again corroborating the idea of injury blockage by the
MSC therapy.
In summary, we have observed a therapeutic effect of
MSC attenuating the progression of CAN when this process
is already in progress. This beneficial effect observed seems
to be attributable to the immunomodulatory properties of
MSCs, which rather than promoting tissue regeneration
prevent the onset of the disease.
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